Gyre Therapeutics, Inc. (GYRE) Fair Value 2026

GYRE · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.6 /10

32 fundamental signals · 8 models active

Value Trap Risk

LOW (30/100)

Quick Summary — As of 2026-08-28, Gyre Therapeutics, Inc. (GYRE) trades at $6.59, versus a $0.42 median fair value across its 8 active models — 93.6% below the current price. QOC: 7.6/10. Value Trap Risk: 30/100 (LOW). 8/13 models active. Within that set, the Bayesian DCF component alone returns $0.18.

Key Facts

Ticker
GYRE
Price
$6.59
Quality Score
7.6/10
Value Trap Risk
30/100
Models Active
8/13
Last Updated
Strength: 8 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Gyre Therapeutics, Inc. (GYRE) Undervalued or Overvalued in 2026?

According to CirclFi’s 8-model valuation engine, Gyre Therapeutics, Inc. (GYRE) appears overvalued as of : the median of 8 independent fair value estimates is $0.42, 93.6% below the current price of $6.59. Estimates range from $0.18 to $0.83. GYRE scores 7.6/10 on fundamental quality and 30/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. GYRE’s -93.6% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Gyre Therapeutics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give GYRE?

8 Intrinsic Value Models vs. Current Price ($6.59)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.18 -97.3%
Ensemble · Low Conviction
 $0.43 -93.5%
Scenario · High Conviction
 $0.83 -87.4%
Intrinsic · High Conviction
 $0.24 -96.4%
Unlock the Full Matrix

Access 4 additional models including EROIC Spread, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 8 Models →

Cancel anytime · No contracts · Instant access

What Is GYRE's Fair Value Range?

Spread across 8 independent models · $0.18 to $0.83

CirclFi's 8 active models place Gyre Therapeutics, Inc. (GYRE) between $0.18 and $0.83 per share, a spread of 155% of the median. The median of that range — $0.42 — is the fair value CirclFi publishes for GYRE, against a current price of $6.59.

Low · Bayesian DCFHigh · First Chicago
$0.18median $0.42$0.83
Where the range comes from
Most bearish modelBayesian DCF$0.18
Most bullish modelFirst Chicago$0.83
Model agreement0 bullish · 8 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for GYRE. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on GYRE, not a CirclFi price target. How each model works →

What Is Gyre Therapeutics, Inc. (GYRE) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Gyre Therapeutics, Inc.'s intrinsic value is estimated at $0.42, suggesting the stock is overvalued at its current price of $6.59. With 8 out of 8 models flagging downside (-93.6% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About GYRE?

8 of 13 models are currently active for GYRE. All 8 active models suggest the stock trades above fair value. Taken together, their median fair value for GYRE is $0.42 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $0.18 on its own, implying -97.3% downside from the current price. See which stocks rank higher →

How Does GYRE Rank in Biotechnology?

Among 625 Biotechnology stocks, GYRE ranks #33 by Quality of Company score. CirclFi's QOC score of 7.6/10 evaluates 32 fundamental signals. A score of 7.6 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Gyre Therapeutics, Inc. competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is GYRE a Value Trap?

CirclFi's Value Trap algorithm assigns GYRE a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

8 of 13 models are active for Gyre Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Gyre Therapeutics, Inc. is rated at 7.6/10. This strong-tier score demonstrates strong fundamentals across the majority of our quality signals.

Models cluster within a tight range (+9.9% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every GYRE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across GYRE's 8 active models, average confidence is 42%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Gyre Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

NVAXNovavax, Inc.QOC 7.7ARWRArrowhead Pharmaceuticals, Inc.QOC 7.6KRYSKrystal Biotech, Inc.QOC 7.8JAZZJazz Pharmaceuticals plcQOC 7.6LGNDLigand Pharmaceuticals IncorporatedQOC 7.9BDTXBlack Diamond Therapeutics, Inc.QOC 7.5AAPGAscentage Pharma Group InternatQOC 5.7SLDBSolid Biosciences Inc.QOC 4.9GUTSFractyl Health, Inc.QOC 4.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: NVAX · ARWR · KRYS · JAZZ · LGND · BDTX · AAPG · SLDB · GUTS · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to GYRE?

7 companies across all industries closest to GYRE’s Quality of Company score of 7.6/10.

HUMHumana Inc.QOC 7.6MHKMohawk Industries, Inc.QOC 7.6QDMIQDM International Inc.QOC 7.6CCCCCC Intelligent Solutions Holdings Inc.QOC 7.6LXULSB Industries, Inc.QOC 7.6BIRKBirkenstock Holding plcQOC 7.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: HUM · MHK · QDMI · CCC · LXU · BIRK · NVDA

Where Does GYRE Sit in CirclFi's Biotechnology Rankings?

GYRE is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Gyre Therapeutics, Inc.’s Valuation?

What is Gyre Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi puts Gyre Therapeutics, Inc. (GYRE)'s intrinsic value at $0.42 — the median of 8 independent model estimates as of 2026-08-28, ranging from $0.18 to $0.83. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $0.18 on its own. The Quality of Company score is 7.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is GYRE overvalued or undervalued right now?

At $6.59, 0 of 8 active models suggest GYRE may be undervalued, while 8 indicate potential overvaluation. The median of all 8 fair value estimates is $0.42, 93.6% below the current price of $6.59 — a consensus view that GYRE is overvalued. The assessment depends on which methodology best fits Gyre Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 7.6 mean for GYRE?

Gyre Therapeutics, Inc.'s QOC of 7.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on GYRE?

CirclFi analyzes GYRE with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 8 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on GYRE?

Of the 8 models currently active on GYRE, First Chicago is the most bullish at $0.83 per share, and Bayesian DCF is the most bearish at $0.18. CirclFi's published fair value for GYRE is the median of that range, $0.42, not either extreme. The gap between the two ends equals 155% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is GYRE a value trap in 2026?

Gyre Therapeutics, Inc.'s Value Trap score is 30/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 8-model valuation engine, Gyre Therapeutics, Inc. (GYRE) has a median fair value of $0.42 — 93.6% below the current price of $6.59 — as of 2026-08-28.” Source: circlfi.com/stock/GYRE/ · Methodology
Primary sources for this GYRE valuation
  • Financial statements: Gyre Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001124105) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for GYRE as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 8 mathematical frameworks give you clarity on GYRE.

Unlock All 8 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for GYRE Unlock All 8 — $39/mo